The marketing authorisation for Dynepo has been withdrawn at the request of the marketing authorisation holder.
Dynepo : EPAR - Summary for the public (PDF/255.76 KB)
First published: 13/03/2008
Last updated: 13/03/2008
|Agency product number||
|International non-proprietary name (INN) or common name||
|Therapeutic area (MeSH)||
|Anatomical therapeutic chemical (ATC) code||
Shire Pharmaceutical Contracts Limited
|Date of issue of marketing authorisation valid throughout the European Union||
Shire Pharmaceutical Contracts Ltd.
Hampshire International Business Park
Basingstoke, Hampshire RG24 8EP
29/02/2008 Dynepo - EMEA/H/C/000372 - II/0020
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Dynepo is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult patients. It may be used in patients on dialysis and in patients not on dialysis.